Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer

Journal of Clinical Oncology

Volumn 19, Issue 2, 2001, Pages 314-321

  Nabholtz, J M ^a   Mackey, J R ^a   Smylie, M ^a   Paterson, A ^a   Noel D R ^a   Al Tweigeri, T ^a   Tonkin, K ^a   North, S ^a   Azli, N ^a   Riva, A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 0035863538     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.2.314     Document Type: Article

References (28)

1. Cancer statistics, 1999
2. Chemotherapy for metastatic disease
3. Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women
4. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer
5. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
6. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer
7. Docetaxel (Taxotere): A review of preclinical and clinical experience. Part II: Clinical experience
8. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
9. Prospective randomized trial of docetaxel versus mitomycin C plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy
10. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer
11. Reporting results of cancer treatment
12. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography
13. Phase II trial of doxorubicin and docetaxel (Taxotere) plus granulocyte colony-stimulating factor (G-CSF) in metastatic breast cancer: An Eastern Cooperative Oncology Group Study (E1196)
14. Phase II study of [TM]Taxotere[/TM] (T) in combination with doxorubicin (A) as first line chemotherapy of metastatic breast cancer
15. Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic
16. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
17. Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion
18. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer
19. Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: The Eastern Cooperative Oncology Group experience
20. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer
21. Phase III trial of doxorubicin vs paclitaxel vs doxorubicin + paclitaxel as first-line therapy for metastatic breast cancer: An intergroup trial
22. Comparison of CAF versus CMFP in metastatic breast cancer: Analysis of prognostic factors
23. Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer
24. Taxotere does not change the pharmacokinetic profile of doxorubicin and doxorubicinol
25. Doxorubicin and [TM]Taxotere[/TM]: A pharmacokinetic study of the combination in advanced breast cancer
26. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer
27. Doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer
28. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC)